JP2022512781A - 同種造血幹細胞移植の方法 - Google Patents

同種造血幹細胞移植の方法 Download PDF

Info

Publication number
JP2022512781A
JP2022512781A JP2021521816A JP2021521816A JP2022512781A JP 2022512781 A JP2022512781 A JP 2022512781A JP 2021521816 A JP2021521816 A JP 2021521816A JP 2021521816 A JP2021521816 A JP 2021521816A JP 2022512781 A JP2022512781 A JP 2022512781A
Authority
JP
Japan
Prior art keywords
antibody
cells
patient
hematopoietic stem
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512781A5 (https=
JPWO2020092655A5 (https=
Inventor
パルチョウデュリー ラーフル
リン プロクター ジェニファー
オー ジラード ジェフリー
ボイタノ アンソニー
ハイツィ シャロン
クック マイケル
ハーティガン アダム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Publication of JP2022512781A publication Critical patent/JP2022512781A/ja
Publication of JP2022512781A5 publication Critical patent/JP2022512781A5/ja
Publication of JPWO2020092655A5 publication Critical patent/JPWO2020092655A5/ja
Priority to JP2024213792A priority Critical patent/JP2025038016A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021521816A 2018-10-30 2019-10-30 同種造血幹細胞移植の方法 Pending JP2022512781A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213792A JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752828P 2018-10-30 2018-10-30
US62/752,828 2018-10-30
US201862773873P 2018-11-30 2018-11-30
US62/773,873 2018-11-30
US201962882362P 2019-08-02 2019-08-02
US62/882,362 2019-08-02
PCT/US2019/058973 WO2020092655A1 (en) 2018-10-30 2019-10-30 Methods for allogeneic hematopoietic stem cell transplantation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213792A Division JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Publications (3)

Publication Number Publication Date
JP2022512781A true JP2022512781A (ja) 2022-02-07
JP2022512781A5 JP2022512781A5 (https=) 2022-11-07
JPWO2020092655A5 JPWO2020092655A5 (https=) 2022-11-07

Family

ID=70462151

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521816A Pending JP2022512781A (ja) 2018-10-30 2019-10-30 同種造血幹細胞移植の方法
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213792A Pending JP2025038016A (ja) 2018-10-30 2024-12-06 同種異系の造血幹細胞移植の方法

Country Status (12)

Country Link
US (1) US20210379195A1 (https=)
EP (1) EP3877415A4 (https=)
JP (2) JP2022512781A (https=)
KR (1) KR20210086683A (https=)
CN (1) CN113301923A (https=)
AU (1) AU2019374055A1 (https=)
BR (1) BR112021008437A2 (https=)
CA (1) CA3117366A1 (https=)
IL (1) IL282637A (https=)
MX (1) MX2021004579A (https=)
SG (1) SG11202104084WA (https=)
WO (1) WO2020092655A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740641A (zh) 2016-11-30 2020-01-31 杰克逊实验室 具有改善的人先天免疫细胞发育的人源化小鼠模型
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
GB202015226D0 (en) * 2020-09-25 2020-11-11 Adc Therapeutics S A Pyrrol obenzodiazepine-antibody conugates and uses thereof
US12496303B2 (en) * 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
US20250041339A1 (en) 2021-11-19 2025-02-06 The Trustees Of The University Of Pennsylvania Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy
AU2022421979A1 (en) * 2021-12-22 2024-08-01 The Jackson Laboratory Humanized mouse models
WO2023118608A1 (en) * 2021-12-23 2023-06-29 Universität Basel Discernible cell surface protein variants of cd45 for use in cell therapy
EP4486784A1 (en) * 2022-03-01 2025-01-08 CSL Innovation Pty Ltd Methods of bone marrow conditioning

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164502A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558662B2 (en) * 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
NZ607906A (en) * 2010-08-18 2015-11-27 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3117367A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Anti-cd45 antibodies and conjugates thereof
WO2020219959A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd45 antibody drug conjugates and uses thereof
JP2022535527A (ja) * 2019-06-04 2022-08-09 マジェンタ セラピューティクス インコーポレイテッド 自己免疫疾患を治療するための方法および組成物
EP4051711A4 (en) * 2019-11-01 2024-02-21 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164502A1 (en) * 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2017219025A1 (en) * 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 128, no. 22, JPN6023042963, 2016, pages 493, ISSN: 0005559702 *
NAT. BIOTECHNOL., vol. 34, no. 7, JPN6023042964, 2016, pages 738 - 745, ISSN: 0005559703 *

Also Published As

Publication number Publication date
CA3117366A1 (en) 2020-05-07
AU2019374055A1 (en) 2021-06-17
JP2025038016A (ja) 2025-03-18
EP3877415A1 (en) 2021-09-15
IL282637A (en) 2021-06-30
BR112021008437A2 (pt) 2021-09-28
KR20210086683A (ko) 2021-07-08
MX2021004579A (es) 2021-07-06
CN113301923A (zh) 2021-08-24
EP3877415A4 (en) 2022-11-30
WO2020092655A1 (en) 2020-05-07
SG11202104084WA (en) 2021-05-28
US20210379195A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
US12291576B2 (en) Anti-CD45 antibodies and conjugates thereof
JP2022512781A (ja) 同種造血幹細胞移植の方法
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
US20220175951A1 (en) Anti-CD45 Antibody Drug Conjugates and Uses Thereof
JP2023116596A (ja) Ｃｄ１１７＋細胞を減少させるための組成物及び方法
JP2021504412A (ja) Ｃｄ５＋細胞の枯渇のための組成物および方法
JP2021500375A (ja) Ｃｄ１１７＋細胞を減らすための組成物及び方法
JP2021500375A5 (https=)
US20240075157A1 (en) Fc silenced antibody drug conjugates (adcs) and uses thereof
KR20220091567A (ko) 항-cd45 항체 및 이의 컨쥬게이트
JP2021504414A (ja) Ｃｄ２＋細胞の枯渇のための組成物および方法
JP2021526525A (ja) 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
JPWO2020092654A5 (https=)
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
US20230390412A1 (en) Compositions and methods for allogeneic transplantation
JPWO2020092655A5 (https=)
JP7791716B2 (ja) Ｔ細胞枯渇治療
JPWO2020219778A5 (https=)
JP2021511333A (ja) Ｃｄ１３４＋細胞の枯渇のための組成物および方法
JP2021517133A (ja) 抗ｃｄ２５２抗体、コンジュゲート、および使用方法
JPWO2020219748A5 (https=)

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240806

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241213

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20260325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260325